The Busiest Dealmakers Of 2022

As 2022 draws to a close, an unusually low number of marquee deals have been made in the biopharma sector. But it has been a hectic year nonetheless, with a high volume of deal-making and the lower valuations reflecting broader economic factors and continuing trends seen in recent years toward smaller, easier-to-manage deals.

Macroeconomic concerns stemming from inflation and rising interest rates, supply-chain uncertainty earlier in the year and the continuing war in...